Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2012Current OncologyOpen Access

Supportive Care Treatments for Toxicities of Anti-EGFR and Other Targeted Agents

View Full Paper
Ask AI
Bookmark
Share

Authors

BMBarbara MeloskyBC Cancer Agency

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Barbara Melosky (2012) studied this question.

synapsesocial.com/papers/6aade72195debff3b14f645chttps://doi.org/10.3747/co.19.1054
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Erlotinib in Previously Treated Non–Small-Cell Lung Cancer2005 · 5,471 citations
  2. 2Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies2007 · 384 citations
  3. 3Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma2009 · 8,322 citations
  4. 4Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>2009 · 1,895 citations